SAN DIEGO--(BUSINESS WIRE)--Amprion, a global leader advancing diagnoses of neurodegenerative disorders, today announced the successful initial $6 million close of a $15 million Series B financing. The round was led by Formation Venture Engineering (FVE) with participation by Eli Lilly and Company and Amprion’s Series A investors.

圣地亚哥--（商业新闻短讯）--推动神经退行性疾病诊断的全球领导者Amprion今天宣布，在1500万美元的B系列融资中，首次成功完成600万美元的融资。这一轮由Formation Venture Engineering（FVE）牵头，礼来公司和安培龙A系列投资者参与。

It will expand Amprion’s commercial reach and enable increased R&D investment to further Amprion’s mission to revolutionize brain disease diagnosis..

它将扩大Amprion的商业范围，并增加研发投资，以进一步推动Amprion彻底改变脑部疾病诊断的使命。。

Amprion has evolved seed amplification testing, which enables the detection of small amounts of misfolded proteins in biological samples, such as cerebrospinal fluid (CSF). Amprion's SAAmplify-ɑSYN biomarker test (formerly SYNTap®) is the only validated seed amplification assay available to help with the diagnosis of synucleinopathies associated with Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with neocortical Lewy body co-pathology.

Amprion已经发展出种子扩增测试，可以检测生物样品（如脑脊液（CSF））中的少量错误折叠蛋白质。Amprion的SAAmplify-SYN生物标志物检测（以前称为SYNTap®）是唯一经过验证的种子扩增检测方法，可用于帮助诊断与帕金森氏病，路易体痴呆和阿尔茨海默病相关的突触核蛋白病与新皮层路易体共病。

Amprion has also partnered with numerous pharma companies to develop therapies for Parkinson’s disease and other neurodegenerative disorders. Recently, the U.S. Food & Drug Administration (FDA) issued a Letter of Support (LoS) recommending the use of the alpha-synuclein (α-syn) seed amplification assay (synSAA) for research and clinical trials..

Amprion还与众多制药公司合作开发帕金森病和其他神经退行性疾病的治疗方法。最近，美国食品和药物管理局（FDA）发布了一份支持函（LoS），建议在研究和临床试验中使用α-突触核蛋白（α-syn）种子扩增试验（synSAA）。。

“We are proud to support Amprion and its mission to truly revolutionize brain disease diagnosis and accelerate precision medicine for neurodegenerative disorders,” said Rahul Bhansali, Managing Partner, FVE. “We believe the shift to diagnosis based on biology, rather than symptomology, will be transformative for patients and clinicians.

FVE的管理合伙人RahulBhansali说：“我们很自豪地支持Amprion及其真正彻底改变脑部疾病诊断和加速神经退行性疾病精准医学的使命。”。“我们相信，转向基于生物学而非症状学的诊断将对患者和临床医生产生变革。

We are excited to support Amprion as they continue to advance their novel technology.”.

我们很高兴支持Amprion，因为他们将继续推进其新技术。”。

Recently published studies in The Lancet Neurology, Alzheimer’s and Dementia, and other leading journals continue to validate the technology, demonstrating the high sensitivity and specificity of Amprion’s SAA for detecting ɑ-synuclein aggregates in CSF – all of which is also confirmed by autopsy.

。

“We are honored to have FVE and Lilly support our team as we work to advance precision medicine for neurodegenerative disorders,” said Russell Lebovitz, MD, PhD, CEO and co-founder of Amprion. “In addition, the strong interest by leading neurology centers and pharmaceutical companies in our mission is indicative of the confidence they have in our technology and in our vision to bring needed clarity to patients and their loved ones with our novel biomarker test.”.

Amprion首席执行官兼联合创始人罗素·勒博维茨（RussellLebovitz）医学博士说：“我们很荣幸能有FVE和礼来支持我们的团队，推动神经退行性疾病的精准医学。”。“此外，领先的神经病学中心和制药公司对我们的使命产生了浓厚的兴趣，这表明他们对我们的技术和愿景充满信心，可以通过我们的新型生物标志物测试为患者及其亲人带来所需的清晰度。”。

Amprion recently submitted its application to New York’s Department of Health which will enable the expansion of its clinical footprint in the United States. In addition, Amprion is reconfiguring its Board to include the addition of up to 3 new members with industry expertise to manage regulatory pathways and better position the company for growth..

Amprion最近向纽约卫生部提交了申请，这将有助于扩大其在美国的临床足迹。此外，Amprion正在重组其董事会，增加多达3名具有行业专业知识的新成员，以管理监管途径，更好地定位公司的发展。。

About SAAmplify-ɑSYN (formerly SYNTap®)

关于SAAmplify-SYN（前身为SYNTap®）

Amprion's SAAmplify-ɑSYN Biomarker Test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with neocortical Lewy body copathology.

Amprion的SAAmplify-SYN生物标志物测试是一流的定性实验室开发测试（LDT），也是唯一可用于诊断突触核蛋白病的种子扩增检测方法，如帕金森氏病（PD），路易体痴呆（LBD/DLB）和阿尔茨海默氏病（AD）与新皮层路易体共病。

The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. SYNTap became commercially available in 2021..

2019年，美国食品和药物管理局（FDA）授予Amprion突破性的设备名称，用于该测试作为PD诊断的辅助手段。SYNTap于2021年上市。。

About Amprion

关于Amprion

Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion’s intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN biomarker test (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies associated with Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease with Lewy body copathology.

Amprion是通过种子扩增测试推进神经退行性疾病诊断的全球领导者。Amprion围绕SAA方法的知识产权扩展到研究，药物开发和商业化。SAAmplify-SYN生物标志物检测（以前称为SYNTap®）是唯一可用于诊断与帕金森氏病，路易体痴呆和路易体病相关的突触核蛋白病的种子扩增检测方法。

Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at https://ampriondx.com/ or find us on LinkedIn..

Amprion还通过帮助生物制药合作伙伴确定新的候选药物和潜在的病理学，加速了神经退行性疾病的精准医学。了解更多信息，请访问https://ampriondx.com/或者在LinkedIn上找到我们。。